Paliperidone extended release for the treatment of pediatric and adolescent patients with Tourette's disorder

Kazuhiko Yamamuro; Manabu Makinodan; Toyosaku Ota; Junzo Iida; Toshifumi Kishimoto

doi:10.1186/1744-859X-13-13

Paliperidone extended release for the treatment of pediatric and adolescent patients with Tourette's disorder

Kazuhiko Yamamuro, Manabu Makinodan, Toyosaku Ota, Junzo Iida, Toshifumi Kishimoto

Research output: Contribution to journal › Article › peer-review

6 Citations (Scopus)

Abstract

Objective: A subgroup of patients with Tourette's disorder (TD) has symptoms refractory to haloperidol, a standard therapeutic drug for TD.Methods: We report on three cases of pediatric and adolescent patients who were treated with paliperidone extended release.Results: In two cases, TD symptoms were remarkably improved by switching from haloperidol to paliperidone extended release, and in another case, paliperidone extended release showed significant efficacy in treating TD symptoms as the first-line drug. In all cases, no significant adverse side effects were detected.Conclusion: Paliperidone extended release may be a strong candidate for the treatment of pediatric and adolescent patients with TD.

Original language	English
Article number	13
Journal	Annals of General Psychiatry
Volume	13
Issue number	1
DOIs	https://doi.org/10.1186/1744-859X-13-13
Publication status	Published - 02-05-2014
Externally published	Yes

All Science Journal Classification (ASJC) codes

Psychiatry and Mental health

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1186/1744-859X-13-13

Cite this

@article{11bf6c069dbd4d99914aa0a4e935e8b4,

title = "Paliperidone extended release for the treatment of pediatric and adolescent patients with Tourette's disorder",

abstract = "Objective: A subgroup of patients with Tourette's disorder (TD) has symptoms refractory to haloperidol, a standard therapeutic drug for TD.Methods: We report on three cases of pediatric and adolescent patients who were treated with paliperidone extended release.Results: In two cases, TD symptoms were remarkably improved by switching from haloperidol to paliperidone extended release, and in another case, paliperidone extended release showed significant efficacy in treating TD symptoms as the first-line drug. In all cases, no significant adverse side effects were detected.Conclusion: Paliperidone extended release may be a strong candidate for the treatment of pediatric and adolescent patients with TD.",

keywords = "Haloperidol, Paliperidone extended release, Tics, Tourette's disorder",

author = "Kazuhiko Yamamuro and Manabu Makinodan and Toyosaku Ota and Junzo Iida and Toshifumi Kishimoto",

year = "2014",

month = may,

day = "2",

doi = "10.1186/1744-859X-13-13",

language = "English",

volume = "13",

journal = "Annals of General Psychiatry",

issn = "1744-859X",

publisher = "BioMed Central Ltd.",

number = "1",

}

TY - JOUR

T1 - Paliperidone extended release for the treatment of pediatric and adolescent patients with Tourette's disorder

AU - Yamamuro, Kazuhiko

AU - Makinodan, Manabu

AU - Ota, Toyosaku

AU - Iida, Junzo

AU - Kishimoto, Toshifumi

PY - 2014/5/2

Y1 - 2014/5/2

N2 - Objective: A subgroup of patients with Tourette's disorder (TD) has symptoms refractory to haloperidol, a standard therapeutic drug for TD.Methods: We report on three cases of pediatric and adolescent patients who were treated with paliperidone extended release.Results: In two cases, TD symptoms were remarkably improved by switching from haloperidol to paliperidone extended release, and in another case, paliperidone extended release showed significant efficacy in treating TD symptoms as the first-line drug. In all cases, no significant adverse side effects were detected.Conclusion: Paliperidone extended release may be a strong candidate for the treatment of pediatric and adolescent patients with TD.

AB - Objective: A subgroup of patients with Tourette's disorder (TD) has symptoms refractory to haloperidol, a standard therapeutic drug for TD.Methods: We report on three cases of pediatric and adolescent patients who were treated with paliperidone extended release.Results: In two cases, TD symptoms were remarkably improved by switching from haloperidol to paliperidone extended release, and in another case, paliperidone extended release showed significant efficacy in treating TD symptoms as the first-line drug. In all cases, no significant adverse side effects were detected.Conclusion: Paliperidone extended release may be a strong candidate for the treatment of pediatric and adolescent patients with TD.

KW - Haloperidol

KW - Paliperidone extended release

KW - Tics

KW - Tourette's disorder

UR - https://www.scopus.com/pages/publications/84900410928

UR - https://www.scopus.com/inward/citedby.url?scp=84900410928&partnerID=8YFLogxK

U2 - 10.1186/1744-859X-13-13

DO - 10.1186/1744-859X-13-13

M3 - Article

AN - SCOPUS:84900410928

SN - 1744-859X

VL - 13

JO - Annals of General Psychiatry

JF - Annals of General Psychiatry

IS - 1

M1 - 13

ER -

Paliperidone extended release for the treatment of pediatric and adolescent patients with Tourette's disorder

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this